Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Anastazia A. Kei, Theodosios D. Filippatos & Moses S. Elisaf. (2016) The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 15:4, pages 559-569.
Read now
Read now
Dragana Nikolic, Peter P Toth, Alessandra Ferlita, Vittoria Di Bartolo, Giuseppe Montalto, Maciej Banach & Manfredi Rizzo. (2014) Novel anti-obesity drugs and plasma lipids. Clinical Lipidology 9:2, pages 179-187.
Read now
Read now
TD Filippatos, CS Derdemezis, PV Voulgari, V Tsimihodimos, MS Elisaf, AD Tselepis & AA Drosos. (2013) Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scandinavian Journal of Rheumatology 42:3, pages 169-175.
Read now
Read now
Simant Baliarsingh, Neha Sharma & Ranadip Mukherjee. (2013) Serum uric acid: Marker for atherosclerosis as it is positively associated with “atherogenic index of plasma”. Archives of Physiology and Biochemistry 119:1, pages 27-31.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Aris P Agouridis, Theodosios D Filippatos, Vasilios Tsimihodimos & Moses S Elisaf. (2011) Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy 9:3, pages 355-366.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
Maria Sarigianni, Niki Katsiki & Dimitri P Mikhailidis. (2010) Ezetimibe in diabetes: more than cholesterol lowering?. Current Medical Research and Opinion 26:10, pages 2517-2520.
Read now
Read now
Giuseppe Derosa, Pamela Maffioli, Sibilla AT Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Angela D'Angelo, Elena Fogari, Ilaria Palumbo, Sabrina Randazzo & Arrigo FG Cicero. (2010) Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opinion on Pharmacotherapy 11:12, pages 1971-1982.
Read now
Read now
Katie S McClendon, Daniel M Riche & Gabriel Ikponmosa Uwaifo. (2009) Orlistat: current status in clinical therapeutics. Expert Opinion on Drug Safety 8:6, pages 727-744.
Read now
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
Read now
M Florentin, EN Liberopoulos, TD Filippatos, C Kostara, A Tselepis, DP Mikhailidis & M Elisaf. (2008) Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opinion on Pharmacotherapy 9:16, pages 2741-2750.
Read now
Read now
Articles from other publishers (37)
Barbora Nussbaumerova & Hana Rosolova. (2023) Obesity and Dyslipidemia. Current Atherosclerosis Reports.
Crossref
Crossref
Sami A. Althwab, Samar A. Alamro, Waleed Al Abdulmonem, Khaled S. Allemailem, Saud A. Alarifi & Essam M. Hamad. (2022) Fermented camel milk enriched with plant sterols improves lipid profile and atherogenic index in rats fed high -fat and -cholesterol diets. Heliyon 8:10, pages e10871.
Crossref
Crossref
Boyan Zhang, Folkert Kuipers, Jan Freark de Boer & Jan Albert Kuivenhoven. (2021) Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. Journal of Clinical Medicine 11:1, pages 4.
Crossref
Crossref
Paraskevi Detopoulou, Tzortzis Nomikos, Elizabeth Fragopoulou & Smaragdi Antonopoulou. (2021) Association of PAF and its Metabolic Enzymes with GGT and the Fatty Liver Index in Healthy Volunteers. Current Vascular Pharmacology 19:6, pages 663-672.
Crossref
Crossref
Soheila Noori, Atieh Mirzababaei, Mohammad Reza Amini, Cain C. T. Clark & Khadijeh Mirzaei. (2021) Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials. International Journal of Clinical Practice 75:11.
Crossref
Crossref
Zlatko Fras & Dimitri P. Mikhailidis. (2021) Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Current Vascular Pharmacology 19:5, pages 451-468.
Crossref
Crossref
Jin Jin, Ruyue Cheng, Yan Ren, Xi Shen, Jiani Wang, Yigui Xue, Huimin Zhang, Xiuhua Jia, Tingting Li, Fang He & Haoming Tian. (2021) Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial. Frontiers in Pharmacology 12.
Crossref
Crossref
Marie-Eve Piché, Isabelle Tardif, Audrey Auclair & Paul Poirier. (2021) Effects of bariatric surgery on lipid-lipoprotein profile. Metabolism 115, pages 154441.
Crossref
Crossref
Shahin Alizadeh-Fanalou, Ali Nazarizadeh, Fatemeh Alian, Parisa Faraji, Bahareh Sorori & Mohsen Khosravi. (2020) Small dense low-density lipoprotein-lowering agents. Biological Chemistry 401:10, pages 1101-1121.
Crossref
Crossref
Rgia A. Othman, Semone B. Myrie, David Mymin, Jean-Baptiste Roullet, Robert D. Steiner & Peter J.H. Jones. (2017) Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Atherosclerosis 260, pages 27-33.
Crossref
Crossref
Ekaterina A. Ivanova, Veronika A. Myasoedova, Alexandra A. Melnichenko, Andrey V. Grechko & Alexander N. Orekhov. (2017) Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity 2017, pages 1-10.
Crossref
Crossref
Theodosios D. Filippatos & Moses S. Elisaf. (2015) Statin–Ezetimibe Combination Therapy In Diabetic Individuals. Angiology 67:6, pages 507-509.
Crossref
Crossref
Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci & Guglielmo M Trovato. (2014) 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA Journal 5:1.
Crossref
Crossref
Priya Sumithran & Joseph Proietto. (2014) Benefit-Risk Assessment of Orlistat in the Treatment of Obesity. Drug Safety 37:8, pages 597-608.
Crossref
Crossref
Heiner K. Berthold, Manfredi Rizzo, Nadine Spenrath, Giuseppe Montalto, Wilhelm Krone & Ioanna Gouni-Berthold. (2014) Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial. PLoS ONE 9:3, pages e91565.
Crossref
Crossref
Theodosios D. Filippatos, Evangelos C. Rizos, Vasilios Tsimihodimos, Irene F. Gazi, Alexandros D. Tselepis & Moses S. Elisaf. (2013) Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes. Lipids 48:6, pages 547-555.
Crossref
Crossref
Dragana Nikolic, Niki Katsiki, Giuseppe Montalto, Esma Isenovic, Dimitri Mikhailidis & Manfredi Rizzo. (2013) Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients 5:3, pages 928-948.
Crossref
Crossref
Elisavet Moutzouri, Evangelos N. Liberopoulos, Matilda Florentin, George Liamis & Moses S. Elisaf. (2012) Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels. Journal of Cardiovascular Pharmacology and Therapeutics 18:1, pages 13-18.
Crossref
Crossref
Antonio Hernández-Mijares, Celia Bañuls, Lorena Bellod, Ana Jover, Eva Solá, Víctor M. Víctor & Milagros Rocha. (2012) Estudio de las subfracciones lipoproteicas tras el tratamiento de simvastatina y ezetimiba, en monoterapia o combinado, en pacientes hiperlipidémicos. Clínica e Investigación en Arteriosclerosis 24:5, pages 217-225.
Crossref
Crossref
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Noboru Tamaki, Hiroaki Ueno, Yuta Morinaga, Tomomi Shiiya & Masamitsu Nakazato. (2012) Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 19:6, pages 532-538.
Crossref
Crossref
Karl Winkler, Stephan Jacob, Tina Müller-Schewe, Michael M. Hoffmann & Thomas Konrad. (2012) Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220:1, pages 189-193.
Crossref
Crossref
Michael S. Kostapanos, Athanasia T. Spyrou, Constantinos C. Tellis, Irene F. Gazi, Alexandros D. Tselepis, Moses Elisaf & Evangelos N. Liberopoulos. (2011) Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. Lipids 46:4, pages 341-348.
Crossref
Crossref
Theodosios D Filippatos. (2011) Role of ezetimibe in non-alcoholic fatty liver disease. World Journal of Hepatology 3:10, pages 265.
Crossref
Crossref
Justin D. Clifton, Edinson Lucumi, Michael C. Myers, Andrew Napper, Kotaro Hama, Steven A. Farber, Amos B. Smith, Donna M. Huryn, Scott L. Diamond & Michael Pack. (2010) Identification of Novel Inhibitors of Dietary Lipid Absorption Using Zebrafish. PLoS ONE 5:8, pages e12386.
Crossref
Crossref
K. Berneis, M. Rizzo, H. K. Berthold, G. A. Spinas, W. Krone & I. Gouni-Berthold. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal 31:13, pages 1633-1639.
Crossref
Crossref
Christos S. Derdemezis, Theodosios D. Filippatos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2010) Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 120-134.
Crossref
Crossref
Matilda Florentin, Evangelos N. Liberopoulos, Costas C. Tellis, Christos S. Derdemezis, Moses Elisaf & Alexandros Tselepis. (2009) Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study. Angiology 61:4, pages 365-371.
Crossref
Crossref
Michalis Kalogirou, Vasilis Tsimihodimos & Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, pages 62-70.
Crossref
Crossref
E. S. Nakou, T. D. Filippatos, A. P. Agouridis, C. Kostara, E. T. Bairaktari & M. S. Elisaf. (2010) The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients. Lipids 45:5, pages 445-450.
Crossref
Crossref
Roberto Fogari, Annalisa Zoppi, Luca Corradi, Paola Preti, Amedeo Mugellini, Pierangelo Lazzari & Giuseppe Derosa. (2010) Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. Hypertension Research 33:3, pages 236-242.
Crossref
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in patients with non-alcoholic fatty liver disease. World Journal of Hepatology 2:4, pages 139.
Crossref
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in obese diabetic patients. World Journal of Diabetes 1:1, pages 8.
Crossref
Crossref
Matilda Florentin, Michael S. Kostapanos, Eleni S. Nakou, Moses ElisafEvangelos N. Liberopoulos. (2009) Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:4, pages 274-282.
Crossref
Crossref
TD Filippatos, CS Derdemezis & MS Elisaf. (2009) Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clinical Lipidology 4:3, pages 331-341.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref